| Cat.No. | Name | Information |
|---|---|---|
| M40697 | NX-5948 | NX-5948 (BTK-IN-24) is an orally active, blood-brain barrier-penetrating, BTK-targeting degradation agent for the study of B-cell malignancies and autoimmune diseases. NX-5948 induces specific BTK protein degradation by the cereblon E3 ligase (CRBN) complex without degradation of other cereblon neo-substrates. NX-5948 mediates potent anti-inflammatory activity via BTK degradation with resultant inhibition of B cell activation. |
| M10423 | DT2216 | DT2216 is a BCL-XL protein hydrolysis targeting chimera (PROTAC) that ligates and degrades BCL-XL with E3 ubiquitin (E3) ligase. DT2216 is effective against a variety of BCL-XL-dependent leukemias and cancer cells. |
| M57168 | QC-01–175 | QC-01-175 is a heterobifunctional molecule, which degrades aberrant tau. |
| M57167 | XY028-133 | XY028-133 is a PROTAC-based CDK4/6 degrader with anti-tumor activity, which consists of ligands for von Hippel-Lindau and CDK. |
| M57166 | PROTAC-O4I2 | PROTAC-O4I2 is a PROTAC targets splicing factor 3B1 (SF3B1). |
| M57165 | FKBP12 PROTAC RC32 | FKBP12 PROTAC RC32 (RC32) is a potent FKBP12 degrader based on PROTAC technology. |
| M57164 | PROTAC ERRα Degrader-3 | PROTAC ERRα Degrader-3 is a potent and selective ERRα degrader based on von Hippel-Lindau ligand. |
| M57163 | PROTAC FKBP Degrader-3 | PROTAC FKBP Degrader-3 is a PROTAC that comprises a FKBP ligand binding group, a linker and an von Hippel-Lindau binding group. |
| M54696 | DGY-09-192 | DGY-09-192 is a bivalent degrader that couples the pan-FGFR inhibitor BGJ398 to the CRL2VHL E3 ligase-recruiting ligand, which induces degradation of FGFR1/2 and largely avoids degradation of FGFR3/4.DGY-09-192 exhibits a nanomolar DC50 against both wild-type FGFR2 and several FGFR2 fusions. In addition, DGY-09-192 has antiproliferative activity in gastric and cholangiocarcinoma cells. |
| M54671 | BTX-6654 | BTX-6654 is a targeted and specific cerebellar-based bifunctional SOS1 PROTAC degrader.BTX-6654 reduces the downstream signaling markers pERK and pS6 and displays antiproliferative activity in a wide range of KRAS-mutant cells. In two KRAS G12C xenograft models, BTX-6654 degraded SOS1 in a dose-dependent manner correlating with tumor growth inhibition, additionally exhibiting synergy with KRAS and MEK inhibitors. |
| M50428 | ND1-YL2 | ND1-YL2 is a PROTAC that selectively degrades SRC-1 via the N-degron pathway. |
| M50174 | KT-294 | KT-294 is a potential first-in-class, PROTAC protein degrader targeting TYK2 for research related to immune system diseases. |
| M50173 | KT-621 | KT-621 is a potential first-in-class, PROTAC protein degrader targeting STAT6 for studies related to immune diseases. |
| M50171 | ARV-102 | ARV-102 is a PROTAC degrader targeting LRRK2 for studies related to Parkinson's disease (PD). |
| M49781 | SJ988497 | SJ988497 is a PROTAC JAK2 degrader. |
| M49780 | SJ1008030 | SJ1008030 is a JAK2 PROTAC which selectively degrades JAK2. |
| M49779 | PROTAC TYK2 degradation agent1 | PROTAC TYK2 degradation agent1 is a potent and subtype-selective TYK2 degrader. |
| M49778 | PROTAC MEK1 Degrader-1 | PROTAC MEK1 Degrader-1 is a PROTAC targeting MEK1 with a pIC50 value of 7.0. |
| M49777 | PPM-3 | PPM-3 is a potent and selective PROTAC ERK5 degrader, with an IC50 of 62.4 nM. |
| M49776 | SJ10542 | SJ10542 is a potent and selective JAK2/3 directing phenyl glutarimide (PG)-PROTAC with DC50s of 14, 11, and 24 nM for JAK2, JAK3, and JAK2-fusion ALL, respectively. |
| M49775 | PROTAC STAT3 degrader-2 | PROTAC STAT3 degrader-2 is a selective and efficacious PROTAC degrader of STAT3 protein with a DC50 of 3.54 μM in Molm-16 Cell. |
| M49774 | AK-2292 | AK-2292 is a potent and selective STAT5 PROTAC degrader, with a DC50 of 0.10 μM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
